| GENERIC NAME | This data is not available for free |
| DESCRIPTION |
Therapeutic Regimen Composed of 3 Components: 1. RituxiMAb 2. In-111 RadioLabeled IbritumoMAb 3. Y-090 RadioLabeled IbritumoMAb |
| INDICATION'S | - Onco.>Lymphoma (L.)>Follicular Lymphoma |
| STATUS |
- Approved in EU & USA - US Patent Expiration: 11.03.13 |
| COMPANY | This data is not available for free |
| MARKETING BY | This data is not available for free |
| PATENT NUMBER | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |